Generex unveils strategic development plan, including Antigen Express spin-out

USA-based Generex Biotechnology (OTC Bulletin Board: GNBT) unveiled  management's strategic development plan for the company's future growth at a press conference this week which included a spin out and two senior management appointments.

Chairman John Barratt said that the board has appointed Mark Fletcher as the company's president and chief executive on a go-forward basis, saying: "The Board has been entirely satisfied with Mr Fletcher's work in that role on an interim basis over the course of a challenging transition period these past six months."

Mr Barratt also noted that the board has appointed David Brusegard as chief operating officer and current vice president of finance, Stephen Fellows, as acting chief financial officer to complete its new management team. Gerald Bernstein will continue as the company's VP for medical Affairs.